[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].
Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M.
Debieuvre D, et al. Among authors: moreau l.
Rev Mal Respir. 2019 Jun;36(6):649-663. doi: 10.1016/j.rmr.2019.03.010. Epub 2019 Jun 14.
Rev Mal Respir. 2019.
PMID: 31204231
French.